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Secretory leukoprotease inhibitor (SLPI) is an anti-inflammatory protein present in respiratory secretions. Whilst epithelial cell
SLPI is extensively studied, neutrophil associated SLPI is poorly characterised. Neutrophil function including chemotaxis and
degranulation of proteolytic enzymes involves changes in cytosolic calcium (Ca2+) levels which is mediated by production of
inositol 1,4,5-triphosphate (IP
3
) in response to G-protein-coupled receptor (GPCR) stimuli.The aim of this study was to investigate
the intracellular function of SLPI and the mechanism-based modulation of neutrophil function by this antiprotease. Neutrophils
were isolated from healthy controls (𝑛 = 10), individuals with cystic fibrosis (CF) (𝑛 = 5) or chronic obstructive pulmonary disease
(COPD) (𝑛 = 5). Recombinant human SLPI significantly inhibited fMet-Leu-Phe (fMLP) and interleukin(IL)-8 induced neutrophil
chemotaxis (𝑃 < 0.05) and decreased degranulation of matrix metalloprotease-9 (MMP-9), hCAP-18, andmyeloperoxidase (MPO)
(𝑃 < 0.05).Themechanismof inhibition involvedmodulation of cytosolic IP
3
production and downstreamCa2+ flux.The described
attenuation of Ca2+ flux was overcome by inclusion of exogenous IP
3
in electropermeabilized cells. Inhibition of IP
3
generation
and Ca2+ flux by SLPI may represent a novel anti-inflammatory mechanism, thus strengthening the attractiveness of SLPI as a
potential therapeutic molecule in inflammatory airway disease associated with excessive neutrophil influx including CF, non-CF
bronchiectasis, and COPD.
1. Introduction
The ability of neutrophils to mobilise rapidly to a site of
infection is paramount to successful elimination of foreign
microbes; however, an excessive infiltrative response can elicit
extensive tissue damage. Indeed, neutrophil migration to
the airways is a feature of a number of chronic pulmonary
disorders including cystic fibrosis (CF) and chronic obstruc-
tive pulmonary disease (COPD), where neutrophil elastase
(NE) is largely responsible for protease-mediated damage in
the lung. A gradient of attractant molecules, including the
bacterial chemotactic peptide fMLP signalling through FPR1
and tissue derived IL-8 signalling via the chemokine receptors
CXCR1 and CXCR2, attract neutrophils to migrate towards
the site of tissue infection in a directional manner referred to
as chemotaxis. Upon cell migration, the normally spherical
cell undergoes lateral polarization to form a leading edge and
a trailing tail [1]. To achieve this morphological change many
processes are initiated including cytoskeletal reorganisation
with protein polymers of filamentous actin, microtubules,
and intermediate filaments forming at the leading edge and
dissolution of polymers occurring at the rear [2].
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Molecular regulation of cytoskeletal rearrangements dur-
ing neutrophil signalling associated with chemotaxis and
degranulation of antimicrobial enzymes, requires an increase
in cytosolic Ca2+ levels [3]. This increase is due to the release
of Ca2+ from the cell’s internal store (the calciosome) or influx
of Ca2+ from the extracellular environment. Signalling via
fMLP or IL-8 GPCRs results in activation of the 𝛽 isoform
of phospholipase C, in turn yielding production of inositol
1,4,5 triphosphate (IP
3
) [4]. IP
3
occupancy of receptors on
calciosomes induces a rapid release of stored Ca2+, and in
a variety of cell types this cascade has been proposed as a
potential target for the treatment of a number of diseases
including heart failure and arrhythmias [5, 6].
Serine protease inhibitors such as SLPI act locally to
maintain a protease/antiprotease balance thereby preventing
protease mediated tissue destruction [7]. Disruption of this
balance is responsible for much of the extracellular matrix
and subsequent lung tissue damage evident in neutrophil
driven lung diseases [8, 9]. SLPI is a well-characterised
member of the trappin gene family of proteins [10]. It is a
highly basic cationic protein that is produced by epithelial
cells of the respiratory tract and is also produced by phago-
cytic neutrophils [11]. SLPI inhibits a broad range of serine
proteases including NE, cathepsin G, trypsin, and tryptase.
Moreover, SLPI possesses anti-inflammatory characteristics
and in monocytes has been shown to inhibit lipopolysac-
charide (LPS)- and lipoteichoic acid-induced nuclear factor
(NF)-𝜅B activation and can compete with p65 for binding
to NF-𝜅B binding sites [12, 13]. Moreover, SLPI has been
shown to directly bind to bacterial LPS thereby down-
regulating production of proinflammatorymediators [14, 15].
However, an area that has received less attention is the
role of neutrophil-derived SLPI in modulating inflammatory
responses.
Studies have localised SLPI within the cytosol [11] and
also in secondary granules of neutrophils, in turn coreleased
with lactoferrin [16]. Moreover, the release of SLPI from neu-
trophils upon phorbol ester (PMA) activation suggests that
neutrophil-derived SLPI may regulate the protease antipro-
tease balance at sites of tissue inflammation [11]. However,
the aim of this study was to investigate the intracellular
function of SLPI within resting and activated neutrophils.
This study has revealed a novel anti-inflammatory role for this
antiprotease and demonstrated the ability of SLPI to modu-
late neutrophilmigration and degranulation by inhibiting IP
3
production and Ca2+ ion mobilisation.
2. Methods
2.1. Chemicals and Reagents. All chemicals and reagents
including inositol 1,4,5-triphosphate were purchased from
Sigma-Aldrich, St. Louis, MO, USA, unless indicated other-
wise. The concentration of SLPI in neutrophil cytosol was
measured using the Quantikine Human SLPI Immunoassay
(R&D Systems, Abingdon, Oxon, UK). Recombinant human
SLPI (rhSLPI) was obtained from R & D Systems, and
recombinant calpain was obtained from Calbiochem (La
Jolla, CA, USA). Human NE was purchased from Elastin
Products Company, Inc. (Owensville, MO, USA). The IP-
One HTRF assay kit was purchased from Cisbio Bioassays
(Bedford, MA 01730, USA).
2.2. Study Groups. Control volunteers (𝑛 = 10, mean age
35.1 ± 1.8) had no underlying medical illnesses and were not
receiving any medication. Prior to recruitment patients with
CF (𝑛 = 5) were exacerbation-free over the preceding 6-week
period, and patients with COPD were being treated for an
acute exacerbation (𝑛 = 5). There were 2/5 and 3/5 males
recruited to the CF and COPD study, respectively. The mean
age was 22.5 ± 2.7 and 56.5 ± 2.7 years for the CF and COPD
groups, respectively. Informed patient consent was obtained
for all procedures, and ethical approval for the use of blood
samples from CF and COPD individuals was obtained from
the Beaumont Hospital Ethics Review Board.
2.3. Preparation of HumanNeutrophils and Cell Fractionation.
Blood was obtained from all donors in 7.5mL heparinised
S-monovette tubes (Sarstedt Ltd, Ireland), and neutrophils
were purified by dextran sedimentation and Lymphoprep
(Axis-Shield PoC AS, Norway) centrifugation as previously
described [17]. Purified cells were resuspended in phosphate-
buffered saline (PBS) (pH 7.4) containing 5mM glucose
(PBSG) and used immediately. The purity of the neutrophil
population was confirmed by flow cytometry measuring the
neutrophil membrane marker CD16b and was found to be
>99% [18]. All in vitro experiments were performed at 37∘C.
Cells were either left unstimulated (control) or activated with
PMA (1.6 𝜇M), fMLP (1𝜇M), and/or IL-8 (1.2 nM, R & D
Systems) for the indicated time points.
For cell fractionation studies, isolated neutrophils were
suspended in Lamberts Break Buffer (LBB) (10mM KCl,
3mM NaCl, 4mM MgCl
2
, and 10mM piperazine-N,N󸀠-
bis(2-ethanesulfonic acid) (PIPES); pH 7.2) containing 10%
(w/w) sucrose and the following protease inhibitors: 13 𝜇M
aprotinin, 5mM benzamidine, 0.15mM N𝛼-Tosyl-L-lysine
chloromethyl ketone hydrochloride (TLCK), 0.5mM N-p-
Tosyl-L-phenylalanine chloromethyl ketone (TPCK), 20mM
N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone
(MeOSuc-AAPV-CMK), 10 𝜇M soybean trypsin inhibitor
(SBTI), orthophenanthroline, and 0.2M pefabloc. Cells were
sonicated 3 times for 5 sec on ice and centrifuged at 500×g
at 4∘C for 5min to generate a post nuclear supernatant
(PNS). The PNS was overlaid on discontinuous sucrose
gradients of 17.5 and 35% (w/w) dissolved in LBB. This was
centrifuged at 137,000×g for 45min at 4∘C. The cytosolic
fraction was removed from above the 17% (w/w) sucrose
layer, and membrane fraction was recovered from the top of
the 34% (w/w) sucrose layer. The pellet (containing primary
and secondary granules) was resuspended in 10% (w/w)
sucrose and overlaid on a discontinuous sucrose gradient of
30, 43, and 55% (w/w). This was centrifuged at 137,000×g for
1 h at 4∘C. Secondary and primary granules were harvested
from above the 43% (w/w) and 55% (w/w) sucrose layers,
respectively, as previously described [18]. The concentration
of protein present in each purified fraction was quantified by
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use of a BCAProtein Assay Kit (Thermo Scientific) according
to the manufacturer’s instructions.
Quantification of F- and G-actin was carried out as
previously described [19]. In brief, neutrophils were either
untreated or treated with SLPI (480 nM) or wortmannin
(100 nM) for 10min and then left unactivated or activated
with IL-8 (1.2 nM) and fMLP (1 𝜇M) for 10min. Neutrophils
were lysed within an F-actin stabilisation buffer containing
ATP (1mM) and protease inhibitors (as indicated above) for
10min at 37∘C. Clarified cell lysates were centrifuged for 2 h
at 100,000×g. The supernatant was removed and the pellet
was resuspended in an equal volume of buffer containing
cytochalasinD (10mM) and incubated on ice for 1 h. An equal
volume of supernatant and pellet was electrophoresed and
Western blotted for actin employing a monoclonal anti-actin
antibody (1.0 𝜇g/mL; Millipore, Billerica, MA, USA).
2.4. Neutrophil Uptake Assays. Native neutrophil cytosolic
SLPI levels were determined by ELISA (SLPI Human ELISA,
Cambridge Bioscience, UK). Uptake of exogenous recombi-
nant human SLPI (rhSLPI; 480 nM) by cells (2 × 105/mL in
PBSG) was performed at 37∘C for 10min. After incubation,
the SLPI loaded cells were washed with ice cold PBSG and
neutrophil levels of cytosolic SLPI measured by ELISA. To
determine the mechanism of SLPI uptake, cell (2 × 105/mL in
PBSG) incubationswere performed at 4∘C for 10min or in the
presence of the endocytosis inhibitors sodium azide (NaN
3
;
15mM) and sodium fluoride (NaF; 10mM) as previously
described [20].
2.5. SDS-PAGE and Western Blot Analyses. Samples were
subjected to SDS-PAGE under denaturing conditions on 4–
12% (w/v) NuPAGE gels (Invitrogen, Carlsbad, CA, USA)
following the manufacturer’s instructions. Routinely 25𝜇g
of neutrophil cytosolic protein, 10 𝜇g of membrane protein,
5 𝜇g secondary granule protein, and 10 𝜇g of primary granule
protein was loaded on each gel. After electrophoresis gels
were stained by Coomassie blue R250 for visualization
of proteins or alternatively proteins were transferred onto
0.2 𝜇m nitrocellulose or PVDF membrane by Western blot-
ting using a semidry blotter for 1 h at 100mA. Membranes
were blocked for 1 h in 3% dry milk (w/v) and 1% (w/v)
bovine serum albumin (BSA) in PBS containing 0.05% (v/v)
Tween 20. Blots were incubated with 1.0 𝜇g/mL polyclonal
rabbit (Rb) anti-SLPI specific antibody (Abcam, Cambridge,
UK), 1.0 𝜇g/mL polyclonal goat (Gt) anti-SLPI (Synergen
Inc., Boulder, Colorado 80301) [21, 22], 1.0 𝜇g/mL polyclonal
goat (Gt) anti-SLPI (R&D Systems), 0.2 𝜇g/mL polyclonal
rabbit anti-myeloperoxidase (MPO), anti-hCAP-18, or anti-
lactoferrin antibody (all purchased fromAbcam, Cambridge,
UK). Additional primary antibodies included 0.2 𝜇g/mL
polyclonal goat antimatrix metalloprotease (MMP)-9 (R & D
Systems), 1.0 𝜇g/mL monoclonal anti-talin-1, and 1.0 𝜇g/mL
monoclonal anti-vinculin or monoclonal anti-actin antibody
(Millipore).The secondary antibodies were HRP-linked anti-
rabbit, -goat, or -mouse IgG (Cell Signalling Technology,
Danvers, MA, USA). Immunoreactive protein bands were
visualized employing SuperSignal West Pico Chemilumines-
cent Substrate (Pierce, Rockford, IL, USA) after exposure to
Kodak X-Omat LS Film.
2.6. Neutrophil Electropermeabilization. Cell permeabiliza-
tion was performed immediately before use of neutrophils
as previously described [23, 24]. In brief, cells (5 × 106)
were washed in hypoosmolar buffer (Eppendorf, UK, Ltd.)
and then resuspended in 400 𝜇L of ice-cold hypoosmolar
buffer in the presence or absence of 1 𝜇M IP
3
. The cells were
then transferred into an electroporation cuvette (2mm gap,
400 𝜇L volume purchased from Eppendorf) and subjected
to three discharges of 300V using an Eppendorf Multi-
porator, with gentle stirring between the three pulses by
pipetting [24]. Permeabilized cells were then incubated at
room temperature for 5min to allow incorporation of IP
3
into
electroporated neutrophils, immediately washed in PBSG,
and then employed in chemotaxis assays or for Ca2+ flux
measurements. Control experiments indicated that the cell
permeabilization procedure did not affect cell viability as
determined by trypan blue exclusion assays.
2.7. Neutrophil Chemotaxis Assays. Chemotaxis assays were
performed by measuring the percentage of neutrophils (2.5
× 105cells/200𝜇L) migrating towards IL-8 (1.2 nM) or fMLP
(1 𝜇M)by employing amultiwell chemotaxis chamber (Neuro
Probe, Inc., USA) and polyvinylprrolidone-free polycarbon-
ate filters (10 𝜇m thick with 5 𝜇m pores). The stimulant was
placed in the lower chamber (total volume of 90𝜇L), and
purified neutrophils were placed in the upper chamber (2.5
× 105cells/200𝜇L) with or without SLPI (0, 120, 240 or
480 nM). Neutrophil chemotaxis was quantified over 30min
at 37∘C. The Neuroprobe chamber was then disassembled,
and the polycarbonate filter was fixed with methanol, and
cells were stained using Speedy-Diff solutions (Clin-tech Ltd,
UK). The number of migrated neutrophils was determined
microscopically employing a Nikon Eclipse TS100 micro-
scope with 10 standardized × 400-high power fields counted
for each well. For comparative analysis neutrophils treated
with IL-8 or fMLP were set at a chemotactic index of 1,
as indicated. Additional experiments were performed after
electropermeabilization with 1𝜇M IP
3
. Cells were then left
unstimulated (control) or challengedwith fMLP or IL-8. Data
was represented as chemotactic index as previously described
[25].
2.8. Measurement of Intracellular Ca2+ Flux. Measurement
of intracellular cytosolic Ca2+ was performed employing the
Fluo-4 NWCalciumAssay Kit (Invitrogen, Bio Sciences Ltd.,
Ireland) in the absence of extracellular Ca2+ according to the
manufactures instructions. In brief, cells (2 × 105/mL) were
incubated for 30min in dye loading solution containing the
Ca2+ sensitive dye Fluo-4. Subsequently, cells were either left
untreated or were exposed to fMLP (1𝜇M) or IL-8 (1.2 nM)
with changes in fluorescence recorded immediately upon
addition of the stimulant. Fluorescence was recorded every
10 sec for 5min employing a Victor X3 (PerkinElmer, Ire-
land) plate reader with excitation wavelength of 490 nm and
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emission at 535 nm. A subset of experiments was performed
by incubating cells with either SLPI (480 nM), the PLC-𝛽
inhibitor U73122 (5𝜇M), or the GPCR inhibitor pertussis
toxin (500 ng/mL), prior to stimulation with fMLP (1mM) or
IL-8 (1.2 nM). Additionally, experiments were performed by
pretreating cells with either SLPI (480 nM) or oxidised SLPI
(480 nM), the later oxidised with 20mM hydrogen peroxide
(H
2
O
2
) as previously described [13].
2.9. Analysis of Neutrophil Degranulation and Secretion of
SLPI. Neutrophils (5 × 106/mL per reaction) suspended
in PBSG remained untreated or preloaded with rhSLPI
(480 nM) for 10min, followed by fMLP/IL-8 (used in com-
bination at 1𝜇M and 1.2 nM, respectively, to ensure release
of primary, secondary, and tertiary granules) stimulation for
10 or 20min. Cell free supernatants were harvested following
centrifugation at 500×g for 5min at 4∘C and analysed for
degranulated proteins: MPO as a marker of primary granule
release, hCAP-18 as a marker of secondary granule release,
and MMP-9 as a marker of tertiary granule release, by
Western blotting. In a subset of experiments the extracellular
release of native cytosolic SLPI was analysed by Western
blotting following cellular activation with PMA (1.6 𝜇M) for
0, 0.5, 1, or 10min or fMLP (1 𝜇M) and IL-8 (1.2 nM) for 0, 10,
20, 30, 40, or 50 sec. Cell free supernatants were harvested as
described above and acetone precipitated prior to SDS-PAGE
and Western blot analysis for SLPI.
2.10. Neutrophil Elastase (NE) and Calpain Activity Assays.
NE (34 nM) activity assays employing the specific sub-
strate N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide as
previously described [26]. Liberation of p-nitroaniline was
measured at 405 nm at 37∘C at 1min intervals for 5min. In
additional studies the NE inhibitory activity of neutrophil
cytosol was assessed before and after immunoprecipitation
of SLPI. For immunoprecipitation experiments, neutrophil
cytosols were obtained from 1 × 107 cells and precleared
by incubation with protein A-Sepharose beads for 1 h as
previously described [18]. Goat polyclonal anti-SLPI (5 𝜇g)
or isotype control IgG was then added to precleared cytosols
for 1 h with rotation at 4∘C. SLPI was then removed from the
cytosol by incubationwith reconstituted proteinA-Sepharose
beads for 1 h, and the anti-NE capacity of the resulting cytosol
(25 𝜇g) was analysed.
Kinetic analysis of calpain activity was determined
using the Calpain-Glo protease assay (Promega Corporation,
Madison, USA) which detects cleavage of the calpain sub-
strate Suc-LLVY-aminoluciferin with luminescence recorded
as per the manufacturer’s instructions. The inhibitory effect
of rhSLPI and calpastatin was analysed over a range of 0–
640 nM and 0–80 nM, respectively.
2.11. Inositol 1,4,5-TriphosphateMeasurements. For analysis of
IP
3
we employed a recognised protocol and measured levels
of IP
1
which accumulates as a stable product of IP
3
[27].
Neutrophils (1 × 105) remained untreated or were preloaded
with SLPI (480 nM) as already described. As positive controls
the PLC-𝛽 inhibitor U73122 (5𝜇M) and the GPCR inhibitor
pertussis toxin (500 ng/mL) were employed prior to stimula-
tion with fMLP (1 𝜇M) or IL-8 (1.2 nM) for 10 sec. Cells were
then lysed, and intracellular IP
1
levels were determined by
use of an IP-One HTRF assay kit in a final reaction volume of
200𝜇L as per the manufacturer’s instructions.
2.12. Flow Cytometry Analysis. Flow cytometry was carried
out to evaluate the membrane expression of CD16b as a
measure of cell purity [18] or CD66b (secondary and tertiary
granules) and CD63 (primary granule) as a measure of
degranulation [24]. Cells remained untreated or were stimu-
lated with fMLP (1𝜇M) and IL-8 (1.2 nM) for 10min at 37∘C.
Neutrophils were then fixed (4% (w/v) paraformaldehyde)
and blocked (2% (w/v) BSA) for 30min at room temperature.
After washing (PBS × 2) neutrophils (1 × 106) were incubated
with 1 𝜇g/100 𝜇L of mouse monoclonal anti-CD16b (Santa
Cruz, Germany), FITC labelled anti-CD66b, or PE labelled
anti-CD63 (both from BD Bioscience, UK). Control samples
were exposed to relevant nonspecific isotype control IgG
or secondary labeled antibody alone (FITC-labelled bovine
anti-mouse). In additional experiments the ability of fMLP
to interact with its cognate receptors on the neutrophil
membrane in the presence of rhSLPI was performed as
previously described [28]. In brief, purified neutrophils (1
× 107/mL) were left untreated or exposed to fMLP (10𝜇M)
or rhSLPI (480 nM) for 1min, followed by incubation with
FITC-labeled fMLP (1𝜇M) for 1min. Cells were washed in
PBS and fluorescence was counted using a BD FACSCalibur
flow cytometer (BD Bioscience, Germany) with a total of
10,000 events acquired. The data were analysed and the
mean fluorescence intensity (MFI) for each experiment was
determined using BD CellQuest Pro software.
2.13. Confocal Immunofluorescence. Adherent neutrophils
were produced by placing neutrophils in PBS on Polysine
microscope slides (AGB Scientific Ltd., Ireland) after which
they were incubated at 37∘C for 5min and then for a further
10min at 37∘C in the presence of fMLP (1 𝜇M) and IL-8
(1.2 nM) or PMA (1.6 𝜇M). Cells were then fixed with 4%
(w/v) paraformaldehyde in PBS for 10min and permeabilised
with 0.2% (v/v) Triton X-100 in PBS for 10min. Subsequently
cells were blocked for 1 h with 1% (w/v) BSA in PBS and
then incubated with 1 𝜇g/mL FITC-labeled rabbit polyclonal
anti-SLPI for 45min and washed in PBS. Cells were mounted
employing VECTASHIELD mounting medium with DAPI
for nuclear staining (Vectashield Lab, UK). Control samples
were exposed to non-specific FITC-labeled isotype control
IgG. All immunofluorescence slides were viewed and images
were acquired using a Zeiss LSM710 confocal immunofluo-
rescence microscope.
2.14. Statistical Analysis. The data was analysed with the
GraphPad Prism version 4.03 for Windows (GraphPad Soft-
ware, San Diego, CA, USA) and results were expressed as
mean± standard error (S.E.) of themean.TheMann-Whitney
𝑈-test or analysis of variance (ANOVA) sample tests followed
by Bonferri correction were employed to identify significant
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differences. Experiments were performed in triplicate, and a
𝑃-value < 0.05 was deemed significantly different.
3. Results and Discussion
3.1. The Immunomodulatory Effects of Cytosolic SLPI on
Neutrophil Migration and Degranulation. SLPI has been
previously reported to exert an anti-inflammatory effect on
immune cell function [20, 29], and in this respect SLPI
has been shown to inhibit monocytic CD4 lymphocyte
proliferation and Th1 cytokine (INF-𝛾) release [30]. Indeed,
T lymphocytes play a key role in the pathogenesis of CF
[31] and COPD [32] lung disease and have been identified as
the predominant cell type in subepithelial bronchial tissue of
CF patients [31]. Th1, Th2, and Th17 cells may augment the
cytokine/chemokine profile in the airways of CF patients thus
contributing to the chronic recruitment of neutrophils [31].
Thus the objective of this study was to investigate whether
SLPI exerted an anti-inflammatory effect on neutrophil
function, and for this reason it was first necessary to confirm
its cellular localisation.
Localisation of SLPI within many cell types known to
produce this protein is still being elucidated. For example,
it has been reported that cellular SLPI is localised in the
nuclei of bronchial epithelial cells exposed to 17𝛽-estradiol
resulting in NF-𝜅B inhibition and IL-8 gene expression
[33]. SLPI has also been detected in the nuclei of alveolar
macrophages in patients with pulmonary sepsis, but not in
healthy controls [20], indicating that the localisation of SLPI
in disease states may differ from healthy control cells. Within
the present study by subcellular fractionation of resting
neutrophils and Western blot analysis employing both rabbit
and goat polyclonal anti-SLPI antibodies, SLPI was identified
as a component of the cell cytosol and secondary granule
fractions (co-localising with lactoferrin) andwas absent from
unstimulated membranes and primary granule fractions
containing MPO (Figure 1(a)). Localization of SLPI to these
compartments is in keeping with previously published data
[11, 16]. As the role of cytosolic SLPI was the focus of ensuing
experiments, we also confirmed the presence of SLPI in
cytosolic fractions of CF and COPD cells (Figure 1(b)).
Having identified the position of SLPI in the neutrophil
further experiments were designed to establish whether
cytosolic SLPI possessed antiprotease activity. Results of
anti-NE kinetic measurements indicated that cytosolic SLPI
contained anti-NE capacity (Figure 1(c)) as both the rate
and total level of NE catalytic activity (34 nM) were negated
by freshly isolated neutrophil cytosol (25𝜇g/10 𝜇L); an effect
significantly reversed in samples in which SLPI was extracted
by immunoprecipitation (Figure 1(c)). At the 240 sec time
point (4min), cytosol that had been subjected to immuno-
precipitation for SLPI removal was 66.7 ± 2.1% less active in
inhibiting NE as compared with complete cytosol (𝑃 < 0.05)
and illustrated no significant difference compared to the NE
control reaction (Figure 1(d)).
To begin to understand the role of intracellular SLPI
in neutrophil cell function our approach was to increase
the level of this anti-protease within the cell cytosol. To
achieve this, cells were resuspended in PBSG containing
exogenous rhSLPI for 10min and then washed to remove
protein that had not been taken up by the cells. To confirm
that rhSLPI was internalized, the concentration of SLPI in
neutrophil cytosolic fractions was determined by ELISA.
Results revealed that addition of 480 nM rhSLPI significantly
raised the concentration of cytosolic SLPI from 96± 6.3 ng to
151 ± 4.8 ng per 1 × 105 cells (𝑃 < 0.05, 𝑛 = 6) indicating
permeability of the cell membrane to exogenous rhSLPI
(Figure 1(e)). To examine internalization of rhSLPI in further
detail experiments were repeated at 4∘C, thereby applying a
temperature block to inhibit transport processes [20]. Under
these reduced temperature conditions results indicated that
the uptake of SLPI and localization to the cell cytosol were
significantly inhibited by 30.2 ± 3.4% (Figure 1(e)). The role
of endocytosis was also assessed by pretreating cells with
the endocytosis inhibitors NaN
3
(15mM) and NaF (10mM)
[20]. These inhibitors had no significant effect on rhSLPI
uptake and cytosolic association (Figure 1(e)). Collectively,
these results indicate that exogenously added rhSLPI is taken
up by the cell and is localized in the cytosol and is not
contained within endosomes. These results are in line with
previously published data on the internalization of rhSLPI by
mononuclear cells [20]. In this later publication exogenously
added rhSLPI was localized to the cytosol and nucleus of
U937 monocytes. SLPI has been characterised as an arginine
rich cationic molecule [34], and it has been reported that
the positively charged nature of the protein facilitates its
transduction across negatively charged membranes [20, 34].
Moreover, investigation of the anti-HIV-1 inhibitory activity
of SLPI has prompted the identification of membrane pro-
teins that are capable of binding to SLPI. In this regard, SLPI
has been shown to interact with the phospholipid binding
protein annexin II on the surface of human macrophage cell
membranes [35] and has also been described as a ligand for
phospholipid scramblases 1 and 4 (PLSCR1 and PLSCR4)
[36]. This later interaction suggested that SLPI disrupts
interplay between PLSCR1 and the CD4 receptor on the
surface of CD4+T lymphocytes thus preventing HIV-1 viral
infection [36].
Within the present study subsequent experiments inves-
tigated the effect of cytosolic SLPI on directional chemotaxis,
a fundamental neutrophil cellular response in terms of
pulmonary inflammation. Cells (2.5 × 105/200𝜇L) were first
preloaded with exogenous rhSLPI (0, 120, 240 or 480 nM),
washed, and then exposed to IL-8 (1.2 nM) or fMLP (1𝜇M),
two stimuli with known effective chemoattractant proper-
ties [37, 38]. As shown in Figures 2(a) and 2(b), rhSLPI
inhibited both IL-8 and fMLP-induced neutrophil directional
chemotaxis in a dose dependent manner with an IC
50
of
approximately 240 nM recorded for both stimuli. Excessive
neutrophil infiltration to the lung is a key pathogenic feature
for disease progression in individuals with CF and COPD.
For this reason we examined the effect of rhSLPI on CF and
COPD neutrophil chemotaxis in response to inflammatory
stimuli in vitro. Results confirmed the inhibitory action on
cell migration and demonstrated that cells preloaded with
rhSLPI showed a markedly reduced capacity to migrate in
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Figure 1: Localization and activity of native SLPI in peripheral blood neutrophils. (a) Coomassie blue stained gel of isolated neutrophils
subjected to subcellular fractionation yielding a cytosol fraction (lane 1), membrane fraction (lane 2), and secondary and primary granule
fractions, lane 3 and 4 respectively. Western blotting employed polyclonal rabbit (Rb) or goat (Gt) antibody to SLPI, which localized SLPI
to both the cytosolic and secondary granule fractions. As controls, MPO and lactoferrin were detected using rabbit polyclonal antibodies as
markers for primary and secondary granules, respectively. (b) Coomassie blue stained gel of isolated CF and COPD neutrophils subjected
to subcellular fractionation yielding a cytosol fraction (lane 1), membrane fraction (lane 2), and pooled primary and secondary granule
fractions (lane 3). Western blotting employed polyclonal Rb antibody confirming cytosolic localization of SLPI in patient samples. (c) The
NE inhibitory activity of neutrophil cytosol was assessed before and after immunoprecipitation (IP) of SLPI using Gt polyclonal anti-SLPI
antibody (Synergen). The kinetics of inhibition is illustrated in (c), and data of the final time point (240 sec) is plotted in (d). Control
experiments included isotype control Gt IgG. ∗𝑃 < 0.05 betweenNE control. (e) Addition of 480 nM rhSLPI to cells (2× 105/mL) increased the
concentration of cytosolic SLPI by approximately 50% above the untreated cells (Con), as determined by ELISA. Experiments were repeated
at 4∘C or in the presence of NaN
3
(15mM) and NaF (10mM). ∗𝑃 < 0.05 between untreated cells (con). Results illustrated in (a) and (b) are
representative gels and blots of 3 separate experiments. Results illustrated in panel (c)–(e) were performed in triplicate and each bar is the
mean ± S.E. (NS, no significant difference, ∗𝑃 < 0.05 calculated by Student’s 𝑡-test).
response to fMLP and IL-8 (Figures 2(d) and 2(c), respec-
tively; 𝑃 < 0.05, 𝑛 = 5). An IC
50
of 611 nM and 376 nM for
CF cells and an IC
50
of 542 nM and 627 nM for COPD cells
were recorded for fMLP and IL-8 stimulation, respectively.
Thus a greater level of SLPI was required to inhibit CF and
COPD neutrophil chemotaxis compared to control cells.This
latter result may be a consequence of neutrophil priming
within the circulation of individuals with CF and COPD due
to persistent inflammation. Indeed, studies have shown that
CFneutrophils are primed and unresponsive to IL-10 induced
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Figure 2: rhSLPI inhibits neutrophil chemotaxis. (a) and (b) An increase in chemotactic inhibition efficiency of increasing concentrations
of SLPI (120, 240, and 480 nM). The chemotactic index represents the ratio of neutrophils that migrated towards fMLP (1 𝜇M) or IL-8
(1.2 nM) over 30min at 37∘C. (c) and (d) fMLP and IL-8-induced mean chemotactic index of neutrophils (2.5 × 105cells/200 𝜇L) isolated
from individuals with CF (𝑛 = 5) or individuals with COPD (𝑛 = 5), in the presence (◻) or absence (◼) of 480 nM SLPI. Results illustrated
were performed in triplicate and each bar is the mean ± S.E. ∗𝑃 < 0.05 or ∗∗𝑃 < 0.01 versus untreated control cells (Con) with statistical
significance calculated by Student’s 𝑡-test.
anti-inflammatory signals [39]. Pseudomonas alginate [40],
TNF-𝛼, and IL-8 have been shown to be important priming
agents forCFneutrophils, causing greater release ofMPO [41]
and NE, compared to neutrophils from control subjects and
individuals with bronchiectasis [42].
The degranulation of proteolytic enzymes and peptides
from the neutrophil upon activation is a tightly regulated
process in order to prevent unnecessary damage to tissues
[43]. For this reason we evaluated the inhibitory effect of
rhSLPI on the kinetics of degranulation. In this experiment
we used fMLP (1 𝜇M) and IL-8 (1.2 nM) in combination
to ensure exocytosis of all three neutrophil granule types
(primary, secondary, and tertiary), and release of granule
proteins was quantified in the extracellular supernatant by
immunoblotting. The use of equal cell numbers (5 × 106/mL)
in each reaction is demonstrated by identical Coomassie
blue stained electrophoretic profiles of whole cell lysates
prepared form cells employed in each reaction (Figure 3(a)).
Levels of cell released MMP-9 from tertiary granules (Fig-
ure 3(b)), hCAP-18 from secondary granules (Figure 3(c)),
8 BioMed Research International
10 20 10 20 10 20
Time (min)
6
14
17
28
(kDa)
62
98
38
Con
fMLP/
IL-8
IL-8/
fMLP/
SLPI
(a)
0
1
2
3
4
M
M
P-
9
(d
en
sit
om
et
ry
 u
ni
ts)
10 20 10 20 10 20Time (min)
Con fMLP/
IL-8
fMLP/
SLPI
IL-8/
10 min
20 min
∗
∗
(b)
0
5
10
15
20
hC
A
P-
18
(d
en
sit
om
et
ry
 u
ni
ts)
*
10 20 10 20 10 20Time (min)
Con fMLP/
IL-8
fMLP/
SLPI
IL-8/
10 min
20 min
(c)
0
2
4
6
8
M
PO
 
(d
en
sit
om
et
ry
 u
ni
ts)
10 20 10 20 10 20Time (min)
Con fMLP/
IL-8
fMLP/
SLPI
IL-8/
10 min
20 min
∗
(d)
0
10
20
30
40
50
60
70
CD
66
b 
(M
FI
)
Control fMLP/
IL-8
fMLP/
SLPI
IL-8/
∗∗∗ ∗∗∗
(e)
CD
63
 (M
FI
)
0
10
20
30
40
Control fMLP/
IL-8
fMLP/
SLPI
IL-8/
∗∗∗ ∗∗∗
(f)
Figure 3: rhSLPI inhibits neutrophil degranulation.Neutrophils (5× 106/mL) isolated fromhealthy individuals were either untreated (Con) or
exposed to SLPI (480 nM), followed by stimulationwith fMLP (1 𝜇M) and IL-8 (1.2 nM) at 37∘C.The use of equal cell numbers in each reaction
is demonstrated by the identical electrophoretic profile of whole cell lysates in the Coomassie blue stained gel (a). Cell free supernatants were
collected at 10 (◻) or 20min (◼) and Western blotted for markers of tertiary ((b), MMP-9), secondary ((c), hCAP-18), or primary granule
release ((d),MPO). (e) and (f), Healthy control neutrophils were fixed in 4% (w/v) paraformaldehyde following 10min IL-8/fMLP stimulation
in the presence or absence of SLPI (480 nM) and analysed by flow cytometry employing a FITC-labeled CD66b (e) or CD63 antibody (f).
Data are represented as mean fluorescent intensity (MFI). All results (expressed as relative densitometry units) were performed in triplicate,
and each bar is the mean ± S.E. A representative Western blot is illustrated. ∗𝑃 < 0.05 between SLPI treated and untreated at the respective
time points calculated by Student’s 𝑡-test.
and MPO from primary granules (Figure 3(d)) were signif-
icantly reduced post 20min stimulation in cells preloaded
with 480 nM rhSLPI (a 60%, 83%, and 80% reduction
respectively, 𝑃 < 0.05). As tertiary granules are more readily
discharged, the inhibitory action of rhSLPI was apparent at
the 10min time point (70% reduction, 𝑃 < 0.05). As an
alternative approach we investigated the membrane expres-
sion of CD66b and CD63. CD66b is a membrane receptor
that is exclusively expressed on the membrane of secondary
and tertiary granules, and CD63 is present on primary
granule membranes [24]. Upon degranulation both CD66b
andCD63 become expressed on the cell surface. As illustrated
in Figures 3(e) and 3(f), membrane expression of CD66b and
CD63 increased by 40% and 180%, respectively, after 10min
fMLP/IL-8 combined stimulation compared to unstimulated
cells (𝑃 < 0.001). In contrast, upregulation of CD66b and
CD63 to the plasma membrane was significantly decreased
in stimulated neutrophils preloaded with SLPI compared to
cells unexposed to SLPI (𝑃 < 0.001). Collectively, this data
successfully demonstrates the inhibitory effect of rhSLPI on
neutrophil chemotaxis and degranulation via IL-8 and fMLP
GPCR signalling.
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Figure 4: SLPI inhibits neutrophil cytoskeletal rearrangements. (a) Immunoblot with anti-actin antibody for the distribution of G-actin (in
the supernatant fraction, S) and F-actin (in the pellet fraction, P) in untreated cells, IL-8/fMLP (1.2 nM/1 𝜇M), SLPI (480 nM), or control
wortmannin (Wort; 100 nM) treated cells.The distribution ratios calculated using constants obtained ofWestern blot densitometry values are
illustrated. (b)The effect of SLPI (480 nM) on talin-1 (190 kDa fragment) or vinculin cleavage (90 kDa fragment) after PMA (1.6𝜇M, positive
control), or IL-8/fMLP activation for 10min was analysed by Western blotting using anti-talin-1 and anti-vinculin monoclonal antibodies.
Equal sample loading was confirmed by Coomassie blue stained gels (top panels) and the 𝛽-actin immunoblots (lower panels). Results of
three separate experiments were expressed as relative densitometry units ((c) and (d)) and each bar is the mean ± S.E. ∗𝑃 < 0.05 between
SLPI treated and untreated cells for the respective stimuli calculated by Student’s 𝑡-test.
3.2. Characterisation of the Mode of Action of SLPI. Remod-
elling of the actin cytoskeleton is a prerequisite for cell
chemotaxis and is a crucial event in the degranulation
process. To study the effect of preloading cells with rhSLPI
on the redistribution of F-versus G-actin after IL-8/fMLP
exposure, a differential centrifugation assay was employed
to analyse in situ F-actin levels. Preloading of cells with
rhSLPI (480 nM) or exposure to wortmannin (100 nM) as
a control [18] suppressed the IL-8/fMLP-induced change in
the ratio of G-actin (supernatant fraction) versus F-actin
(pellet fraction) (Figure 4(a)). In addition, as the C-terminal
fragment of talin (190 kDa) is an actin nucleating protein
which binds to G-actin and also the fact that cleavage of
talin-1 is critical to focal adhesion disassembly [44], we
investigated the possibility that SLPI regulates neutrophil
chemotaxis by affecting talin cleavage. Neutrophils which
were either untreated or preloaded with rhSLPI (480 nM/1
× 107 cells) were stimulated with PMA (positive control) or
fMLP/IL-8 for 10min, and the level of talin-1 cleavage was
assessed by immunoblotting using a mousemonoclonal anti-
talin-1 antibody (Figure 4(b)). Site-specific cleavage of talin-
1 yielding a 190 kDa fragment was observed in fMLP/IL-8
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and PMA activated whole cell lysates, an effect consistently
inhibited by preloading cells with rhSLPI (50% and 64%
inhibition, resp.), (Figure 4(c), 𝑃 < 0.05). Moreover, we eval-
uated the effect of rhSLPI on vinculin cleavage, a protein
involved in neutrophil adhesion and pseudopod formation
[45]. Results revealed that vinculin cleavage in response
to fMLP/IL-8 and PMA was significantly reduced in cells
preloaded with rhSLPI, as demonstrated by Western blot
analysis (Figure 4(b)) and densitometric quantification (96%
and 84% inhibition, respectively, Figure 4(d)).
The observation that rhSLPI could inhibit talin and
vinculin cleavage prompted us to initially investigate the
hypothesis that SLPI inhibited the Ca2+ dependent neutral
cysteine protease activity of calpain-1 and calpain-2, which
play an important role in cell migration by cleaving talin and
vinculin [46]. SLPI has been shown to inhibit a broad range
of serine proteases [47], but, unlike the antiprotease alpha-1
antitrypsin (AAT), SLPI has not been shown to inhibit other
protease classes. For example, AAT has been shown to inhibit
caspase-3 activity [48] and to modulate metalloprotease
ADAM-17 activity, thereby regulating neutrophil chemotaxis
in response to soluble immune complexes [18]. However,
unlike AAT or the natural inhibitor calpastatin, which have
been shown to inhibit neutrophil calpain [49], the results
of the present study demonstrate that SLPI had no direct
effect on calpain-1 or calpain-2 activity (see Supplemen-
tary Figure 1 in Supplementary Material available online on
http://dx.doi.org/10.1155/2013/560141).
Upon activation of neutrophils in the absence of extra-
cellular Ca2+, the rise in cytosolic Ca2+ levels occurs by
release from intracellular sites. As a result of the rise in Ca2+,
the neutrophil initiates cytoskeletal rearrangements required
for degranulation and chemotaxis [50]. Therefore, we next
explored the possibility that SLPI inhibits activation of neu-
trophils by regulating Ca2+ mobilisation from intracellular
stores. Preloading neutrophils (2 × 105/mL) isolated from
healthy individuals with rhSLPI (480 nM) in a Ca2+ free
buffer significantly inhibited the rise in cytosolic Ca2+ levels
from intracellular stores triggered by fMLP (Figure 5(a), 𝑃 <
0.01 at 10 sec and 𝑃 < 0.05 at 20 sec) and IL-8 (Figure 5(b),
𝑃 < 0.05 at 20 and 30 sec) compared to untreated control
cells. Of note, the observed spike in Ca2+ flux in healthy con-
trol cells not treated with SLPI is consistent with previously
published data [18]. Furthermore, neutrophils isolated from
CF stable individuals preloaded with rhSLPI also failed to
initiate aCa2+ spike upon stimulationwith fMLP (Figure 5(c),
𝑃 < 0.05 at 10 and 20 sec) or IL-8 (Figure 5(d), 𝑃 <
0.01 and 𝑃 < 0.05 at 10 and 20 sec, resp.). Additionally,
when Ca2+ levels were analysed in neutrophils isolated from
individuals during an acute exacerbation of COPD, there was
a statistically significant decrease in the cytosolic Ca2+ levels
of fMLP and IL-8 stimulated cells preloaded with rhSLPI
(480 nM) compared to untreated cells (𝑃 < 0.05 at 10 and
20 sec, Figures 5(e) and 5(f)). Taken together, these results
indicate that cytosolic SLPI inhibits Ca2+ flux in cells from
patients or healthy donors when exposed to proinflammatory
stimuli.
To rule out the possibility that SLPI inhibits Ca2+ flux
in cells by preventing IL-8 and fMLP interacting with their
respective receptors, studies on agonist-receptor interactions
were performed. Whilst exposure to FITC-labeled fMLP
resulted in specific binding of FITC-fMLP on neutrophil
membranes by flow cytometry (Figures 6(a) and 6(b), pre-
exposure of cells (1 × 107/mL) to unlabeled fMLP prevented
FITC-fMLP binding thereby reducing the mean florescence
intensity reading by approximately 75% (40.05 ± 4.7 to 11.04
± 1.45 MFI, Figures 6(a) and 6(b)). In contrast, pre-loading
of neutrophils with rhSLPI (480 nM) had no effect on the
FITC-fMLP fluorescence reading (42.67 ± 4.164 compared
to 40.05 ± 4.471 in the presence of SLPI), indicating that
the immuno-regulator activity of SLPI was not a result of
inhibiting fMLP binding to the cell membrane. Additionally,
results indicated that preloading cells with rhSLPI did not
impair IL-8 membrane binding (results not shown). More-
over, reaction with H
2
O
2
, a major oxidant generated by
activated neutrophils, oxidizes all fourmethionine residues in
SLPI, resulting in substantial diminution of its NE inhibitory
activity [13]. In the present study, oxidised rhSLPI possessed
decreased inhibitory capacity over intracellular Ca2+ flux
upon activation with fMLP (1 𝜇M) or IL-8 (1.2 nM, Figures
6(c), 6(b), and 6(d)) suggesting the requirement of the active
site of SLPI for the observed inhibitory effect on Ca2+ flux.
In response to either fMLP or IL-8 the initial rise in
intracellular cytosolic Ca2+ requires IP
3
production, and sub-
sequent IP
3
occupancy of receptors on calciosomes induces
a rapid release of Ca2+ [51, 52]. Therefore, we next explored
the possibility that cytosolic rhSLPI inhibits Ca2+ cytosolic
flux by preventing upstream IP
3
production. For this analysis
we measured levels of IP
1
which accumulates as a stable
product of IP
3
[27]. Pre-loading of neutrophils (1 × 105/mL)
with rhSLPI (480 nM) significantly reduced cumulative levels
of IP
1
upon fMLP or IL-8 activation (an approximate 75%
reduction for both stimuli, 𝑃 < 0.05), with similar levels to
unstimulated cells observed (Figure 7(a)). Positive controls
for this experiment included addition of the PLC-𝛽 inhibitor
U73122 (5 𝜇M) or the GPCR inhibitor pertussis toxin (PTX,
500 ng/mL), with significant inhibition of IP
1
accumulation
observed for both (𝑃 < 0.05). Substantiating this result, it
was observed that the inhibitory effect of rhSLPI (480 nM)
on Ca2+ flux induced by fMLP and IL-8 was overcome
by augmenting cytosolic levels of IP
3
(1 𝜇M) (Figure 7(b)).
For this latter experiment IP
3
was incorporated into elec-
troporated neutrophils and the cells immediately employed
in Ca2+ flux measurements. Moreover, results revealed that
rhSLPI employed at a concentration of either 240 or 480 nM
was unable to reduce the chemotactic index of cells loaded
with IP
3
in response to either fMLP (Figure 7(c)) or IL-8
(Figure 7(d)).
Collectively, these results confirm that cytosolic SLPI
did not impede agonist receptor interaction but success-
fully modulated IP
3
production and subsequent release of
Ca2+ from IP
3
-regulated internal stores. However, as the
production of IP
3
is a direct outcome of PLC-𝛽 activation,
further experiments are required to fully understand how
SLPI modulates PLC-𝛽 activation. Moreover, it is possible
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Figure 5: SLPI inhibits intracellular Ca2+ flux. Neutrophils (2 × 105/mL) were isolated from healthy donors ((a) and (b)), individuals with
CF ((c) and (d)) or COPD ((e) and (f)) (𝑛 = 5 for each cohort). Cells remained untreated (control, con) or treated with 480 nM SLPI for
5min prior to stimulation with fMLP (1𝜇M) or IL-8 (1.2 nM) for 10, 20, 30, 40, or 50 sec. Intracellular cytosolic Ca2+ was analysed using the
Invitrogen Fluo-4NW Calcium Assay kit. Each point is the mean ± S.E. (𝑛 = 5, ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 between untreated and SLPI
treated cells calculated by 2 way ANOVA followed by Bonferroni test).
that SLPI affects Ca2+ flux via modulation of other immune
signalling pathways including the mitogen-activated protein
kinase (MAPK) cascade, ERK1/2 and p38 MAPK [53–55],
modulation of the increase in intracellular Ca2+ associated
with activation of the transcription factor NF-𝜅B [56], or
by regulation of cAMP-dependent protein kinase A [3].
Nevertheless, the maintenance of intracellular Ca2+ levels
via IP
3
modulation represents a novel therapeutic strategy
in inflammatory conditions such as COPD and CF, where
neutrophil infiltration to the airways causes excessive tissue
damage. In line with this theory, U73122, a membrane per-
meable aminosteroid PLC inhibitor, whichwe have been used
as a positive control in this study, has previously been shown
in an in vivo animal model to significantly inhibit neutrophil
infiltration to the peritoneal cavity upon LPS injection, in
addition to reducing IL-8 and leukotriene B
4
induced Ca2+
flux in neutrophils [57]. The findings of the present study are
highly relevant in the consideration of rhSLPI as a modulator
of Ca2+ flux and therapeuticmodality in chronic neutrophilic
airway inflammatory disorders. In support of this concept
applications of aerosolized anti-proteases such as SLPI have
been investigated as potential therapeutics for people with CF
and COPD [58, 59]. Aerosolized rhSLPI (100mg, twice daily
for 1 week) has previously been administered to individuals
with CF [59] with results revealing increased epithelial lining
fluid levels of SLPI and significantly reduced levels of active
NE (pretreatment 11.1 ± 1.8 𝜇M NE to posttreatment 6.1 ±
1.2 𝜇M NE). A further in vivo study carried out in rats
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Figure 6: Intracellular nonoxidised SLPI exerts immunomodulatory activity. (a) Neutrophils (1 × 107/mL) were exposed to unlabeled fMLP
(10𝜇M) or SLPI (480 nM) for 1min, followed by FITC-labeled fMLP (fMLP󸀠󸀠) (1 𝜇M), and the level of bound fMLP󸀠󸀠, quantified by FACS.
The negative control (unlabeled cells) is illustrated in dark grey and a total of 10,000 events were collected. (b) Results in mean fluorescence
intensity units (MFI) demonstrate that pre-incubationwith unlabeled fMLP, but not rhSLPI, prevented binding of fMLP󸀠󸀠 to the cellmembrane
(∗𝑃 < 0.05 compared to fMLP/fMLP󸀠󸀠 cells). (c) and (d); Neutrophils (1× 107/mL) remained untreated or treated with 480 nMSLPI or 480 nM
oxidised SLPI (ox-SLPI) for 5min, prior to stimulation with fMLP ((c), 1𝜇M) or IL-8 ((d), 1.2 nM). Ox-SLPI did not inhibit the fMLP or IL-8
induced Ca2+ flux (∗𝑃 < 0.05 between SLPI and ox-SLPI). Each experiment was performed in triplicate, each point is the mean ± S.E. and
statistical significance was calculated by 2-way ANOVA followed by Bonferroni test or Student’s 𝑡-test.
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Figure 7: SLPI inhibits production of IP
3
. (a) Preloading neutrophils (1 × 105/mL) with SLPI (480 nM) significantly reduced the accumulative
levels of IP
1
induced by fMLP (1 𝜇M) or IL-8 (1.2 nM) activation (final reaction volume of 200𝜇L). Positive controls included U73122 (5 𝜇M)
and pertussis toxin (PTX, 500 ng/mL). (b) Cells remained untreated or preloaded with SLPI (480 nM), electropermeabilized in the presence
or absence of 1 𝜇M IP
3
and then stimulated with fMLP (1𝜇M) or IL-8 (1.2 nM) for 10 sec. (c) and (d) Neutrophils were isolated from healthy
individuals and the effect of SLPI (240 or 480 nM) on the cell chemotactic index induced by fMLP (1 𝜇M) or IL-8 (1.2 nM) was determined
in the presence (◼) or absence (con, ◻) of 1𝜇M IP
3
. SLPI had no significant inhibitory effect on neutrophil chemotaxis in the presence of
augmented cytosolic IP
3
. Each point is the mean ± S.E. (𝑛 = 5, NS: no significant difference, and ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 calculated by
Student’s 𝑡-test).
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Figure 8: SLPI is secreted from the cell upon activation. (a) Coomassie Blue stained gel (top panel) and immunoblots (bottom 2 panels)
employing anti-SLPI antibody (Gt, Synergen) for its respective distribution (intracellular or extracellular) in control unstimulated cells (Con)
and after IL-8 (1.2 nM) and fMLP (1𝜇M) or PMA (1.6𝜇M) activation for 10min. (b) Donor neutrophils (5 × 106/mL) were stimulated with
PMA (1.6𝜇M) for 0, 0.5, 1, or 10min before sonication and preparation of membrane (top panels) and extracellular released protein fractions
(bottompanels). SLPI and p47phox translocationwas analysed byWestern blotting employing polyclonal rabbit antibodies. (c)The distribution
of SLPI in resting unstimulated cells (Con) and after PMA or fMLP (1 𝜇M) and IL-8 (1.2 nM) activation for 10min was detected using an FITC
labeled rabbit polyclonal anti-SLPI antibody (green fluorescence).The distribution of SLPI was predominantly cytosolic in unstimulated cells,
and after stimulation condensed around the margin of the cell (indicated by white arrow). DAPI stained nuclei are represented in blue (×40
magnification, ×10 zoom). (d) Coomassie blue stained gel (top panel) and immunoblot (bottom panel) employing rabbit anti-SLPI antibody
for detection of released SLPI in the extracellular supernatants of unstimulated (Un) or fMLP/IL-8 stimulated (Stim) healthy control (Con),
COPD or CF cells (5 × 106/mL). (e) Neutrophils isolated from healthy donors were incubated at 37∘C and were treated with fMLP/IL-8.
Cell free supernatants were collected at 0, 10, 20, 30, 40 or 50 sec and Western blotted for cell secreted SLPI (top panel) and intracellular
cytosolic Ca2+ was analysed using the Invitrogen Fluo-4 Calcium Assay kit. Results of three separate experiments were expressed as relative
densitometry units (bar graph), and each bar is the mean ± S.E. ∗𝑃 < 0.05 is between 0 time point and statistical significance was calculated
by Student’s 𝑡-test.
reported that rhSLPI could remain biologically active in the
lungs for at least 8 h [60].When administered intratracheally,
(8.6mg/kg) the reported half-life of SLPI was 4 to 5 h,
indicating minimal metabolism in the airways. rhSLPI has
also been administered intravenously to sheep [21]. In this
latter study, following an infusion of rhSLPI (1 g) over 10min
the half-life of rhSLPI was reported as 1.8 h; however if the
rate of infusion was slowed, SLPI excretion was significantly
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Figure 9: SLPI regulates neutrophil activity by modulating IP
3
production. (a); Upon neutrophil stimulation SLPI is secreted from the
cell to the extracellular environment and IP
3
is formed during PLC-𝛽 activation. IP
3
binds to Ca2+ voltage-gated channels on calciosomes
(or endoplasmic reticulum) and allows Ca2+ ions to flow from the lumen of the calciosome toward the cell interior. The presence of Ca2+
ions within the cytosol allows cytoskeletal rearrangements such as actin polymerization and talin cleavage facilitating the process of cell
degranulation and chemotaxis. (b); Exogenously added rhSLPI effectively accumulates within the cell and reduces IP
3
production thereby
inhibiting degranulation of antimicrobial peptides and proteins and cell migration.
decreased with a 3 h infusion associated with 9% excretion
[21]. Intact SLPI was detected in lymph and epithelial lining
fluid, which displayed anti-NE capacity in line with the levels
of SLPI [21].
3.3. Secretion of SLPI from the Neutrophil Coincides with
Cell Activation. The question next investigated was how
cells overcome the inhibitory effect of native cytosolic SLPI
thereby leading to Ca2+ flux in neutrophils. Indeed, neu-
trophils have previously been shown to secrete SLPI [11],
and for this reason ensuing experiments were designed to
determine whether the kinetics of SLPI release upon cell
activation corresponded to the spike of Ca2+ flux. ByWestern
blotting, it was found that neutrophils (5 × 106/mL) secrete
cytosolic SLPI to the outside of the cell in response to both
IL-8 (1.2 nM) and fMLP (1 𝜇M) or PMA (1.6 𝜇M) activation
for 10min (Figure 8(a)). A reduction in the level of cytosolic
SLPI was observed, most prominently after PMA activation,
with a concomitant increase in the level of extracellular
SLPI detected. These results are in keeping with a previous
study that recorded significant amounts of SLPI secreted
from activated neutrophils (3 𝜇g/106 cells/24 h) as compared
with an epithelial and type II pneumocyte cell line [11]. This
set of experiments were expanded and included subcellular
fractionation and isolation of membranes following cell (5
× 106/mL) activation with PMA (1.6𝜇M) at 0, 0.5, 1, and
10min. Results revealed that over the timecourse explored,
progressively higher quantities of SLPI became associated
with the plasma membrane (Figure 8(b) upper panel) fol-
lowed by sequential secretion to the outside of the cell (Fig-
ure 8(b) lower panel). Translocation of the NADPH oxidase
component p47phox from the cytosol to the membrane upon
cell activation was used as a positive control [61]; however
p47phox was not released from the cell. To corroborate results,
confocal microscopy was employed and revealed that SLPI
was localized diffusely and uniformly throughout the cytosol
of control resting cells (green). In contrast, after fMLP/IL-8 or
PMA stimulation for 10min themajority of SLPI translocated
to the periphery of the cell (Figure 8(c)). Moreover, a greater
level of SLPI secretion from CF and COPD neutrophils
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(5 × 106/mL) was detected in extracellular supernatants by
Western blot analysis (Figure 8(d)). This latter result is in
agreement with data indicating a requirement for increased
SLPI for modulation of COPD and CF neutrophil activity
(Figures 2(c) and 2(d)) possibly due to the occurrence of
cell priming. On the assumption that extracellular release
of SLPI must follow the same time course of seconds as
Ca2+ flux, we monitored release of SLPI from the cell after
10, 20, 30, 40, and 50 sec fMLP/IL-8 stimulation. Release
of SLPI was quantified in the extracellular supernatant
by immunoblotting and results demonstrate that levels of
extracellular SLPI were significantly increased after just 10 sec
stimulation (Figure 8(e), 𝑃 < 0.05). Although the time
course of Ca2+ flux peaked at 10 sec, a lag period of 30 sec for
the maximum level of detectable cell free SLPI was evident.
This may in part be explained by the time required for
immunodetection of measurable amounts of the protein on
the outside of the cell.
SLPI release from the cell following activation has been
comprehensively studied [11]; however the signalling events
including possible phosphorylation of SLPI and necessary
membrane receptor interactions required for its release, have
yet to be evaluated. Nevertheless, collectively these results
indicate that upon exposure to proinflammatory stimuli
cytosolic SLPI is actively secreted from the cell, and the time
of elimination of SLPI coincides with the time of Ca2+ flux.
4. Conclusion
This study presents evidence that SLPI is present in the
cytosol and also the secondary granules of resting neutrophils
and is secreted from the cell upon exposure to the phagocyte
activator PMA or the chemokines IL-8 and fMLP. We show
that neutrophil cytosolic SLPI is effective as a serine protease
inhibitor with potent activity against NE. Moreover, within
the neutrophil SLPI maintains the ability to modulate cellu-
lar processes involving cytoskeletal restructuring including
directional chemotaxis and degranulation of antimicrobial
peptides and proteases. This investigation elucidates a hith-
erto undescribed function of intracellular neutrophil cytoso-
lic SLPI and indicates that the described anti-inflammatory
effects of SLPI may be orchestrated through inhibition of
Ca2+ flux by modulating IP
3
production (Figure 9). Due
to the correlative relationship between neutrophil activation
and cytosolic Ca2+ levels, inhibition of Ca2+ flux by SLPI
may pose as a potential anti-inflammatory therapy during
acute exacerbation of severe chronic obstructive lung disease,
thereby reducing neutrophil influx into the airways.
SLPI, elafin, and AAT have been a focus of interest from
a therapeutic viewpoint for a number of years. Modifying
excessive neutrophil activation and an overexuberant inflam-
matory response would be a relevant treatment objective in
a wide variety of conditions including COPD and CF and
also in the modulation of periodontal disease, sepsis syn-
dromes, asthma, bronchiectasis, and in transplant rejection.
Recent studies have employed aerosolized liposomal [62] and
hydrogel [63] formulations for successful delivery of SLPI.
Our finding demonstrating the inhibitory capacity of SLPI on
IP
3
production and Ca2+ flux strengthens its attractiveness as
a potential therapeutic, and the finding that SLPI has an anti-
inflammatory role via inhibition of neutrophil chemotaxis
and degranulation is a novel concept that opens up a newfield
of investigation.
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